Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase

Sande, Marleen G H van de; Hair, Maria J. H. de; Leij, Christiaan van der; Klarenbeek, P L; Bos, Wouter H; Smith, Malcolm D.; Maas, Mario; Vries, Niek de; Schaardenburg, D. van; Dijkmans, Ben A. C.; Gerlag, Daniëlle M.; Tak, Paul‐Peter

doi:10.1136/ard.2010.139527

Cited by 184 publications

(136 citation statements)

References 36 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…91 A positive ACPA status in those with arthralgia is associated with the subsequent development of arthritis in only about 20-30% of these people after 30 months of follow up. 92,93 The synovial tissue of patients who are at risk of arthritis has also been examined in two relatively small studies Little evidence of synovitis was found in the first and subtle T-cell infiltration was noted in the second. 94 Data on alternative tissues such as lung and lymph node that may be important in the very early stages of arthritis as sites of first antigen presentation.…”

Section: Early Arthritis and Early Diagnosismentioning

confidence: 99%

Synovial tissue research: a state-of-the-art review

et al. 2017

View full text Add to dashboard Cite

The synovium is the major target tissue of inflammatory arthritides such as rheumatoid arthritis (RA). The study of synovial tissue has advanced significantly over a number of decades from arthroplasty, blind needle biopsy and more recently facilitated by arthroscopic and ultrasonographic technology that allows easier visualisation and improves the reliability of obtaining synovial biopsies. The potential for study of pathogenesis, patient stratification, discovery of biomarkers and novel targets, as well as validation of therapy, have all been progressed rapidly in the last decade, facilitated by increasingly diverse and sophisticated analytical and technological approaches. In this review we describe clinical and translational developments in the field of synovial tissue research, outlining current and novel investigative technologies, and highlight their application to advance our understanding of the aforegoing imperatives.3

show abstract

Section: Early Arthritis and Early Diagnosismentioning

confidence: 99%

Synovial tissue research: a state-of-the-art review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The main characteristic of the disease is joint inflammation. 1,2 It has a slow progressive course leading to a more severe stage at which cartilage and bone destruction are observed. RA occurs in » 1% of the overall population, and it is more common in women than in men.…”

Section: Introductionmentioning

confidence: 99%

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab

Aira

Hernández

Prada³

et al. 2015

mAbs

View full text Add to dashboard Cite

(2016) Immunological evaluation of rheumatoid arthritis patients treated with itolizumab, mAbs, 8:1, 187-195, DOI: 10.1080/19420862.2015 To link to this article: https://doi.org/10. 1080/19420862.2015 Rheumatoid arthritis is an autoimmune disease characterized by joint inflammation that affects approximately 1% of the general population. Itolizumab, a monoclonal antibody specific for the human CD6 molecule mainly expressed on T lymphocytes, has been shown to inhibit proliferation of T cells and proinflammatory cytokine production in psoriasis patients. We have now assessed the immunological effect of itolizumab in combination with methotrexate in rheumatoid arthritis by analyzing clinical samples taken from 30 patients enrolled in a clinical trial. T and B cell subpopulations were measured at different time points of the study. Plasma cytokine levels and anti-idiotypic antibody response to itolizumab were also evaluated. The combined treatment of itolizumab and methotrexate led to a reduction in the frequency of T cell subpopulations, and plasma levels of proinflammatory cytokines showed a significant decrease up to at least 12 weeks after treatment ended. No anti-idiotypic antibody response was detected. These results support the relevance of the CD6 molecule as a therapeutic target for the treatment of this disease.

show abstract

“…Magnetic resonance imaging (MRI) biomarkers have also been investigated in autoantibody-positive individuals at risk of arthritis development. In one prospective cohort, no MRI evidence of synovial inflammation was found in the knee joints of seropositive, atrisk individuals (8,60). However, imaging of the small joints of the hands and feet has yielded different results.…”

Section: Imaging In Pre-ra: Significance Of Subclinical Inflammation mentioning

confidence: 99%

“…The fact that autoantibodies can be detected prior to clinical, imaging, or histologic evidence of joint involvement (8) suggests that their origin is likely to be distant to the joints. The discovery of well-developed IgA ACPA responses in at-risk individuals and in the stored serum of RA patients obtained at the preclinical phase suggests that immune events at mucosal surfaces occur in the earliest phases of RA and may precede systemic autoimmunity (9)(10)(11).…”

Section: Localized Autoimmunity: Initiating Events At Mucosal Surfacesmentioning

confidence: 99%